Rufinamide 200 mg/1 (Rufinamide TABLET, FILM COATED) 200 mg/1

Rufinamide 200 mg tablets are an anticonvulsant medication used to manage seizures. This film-coated oral tablet is manufactured by Camber Pharmaceuticals, Inc. in the USA.

Strength

200 mg/1

Pack Size

120 TABLET, FILM COATED in 1 BOTTLE (31722-598-12)

Manufacturer / TM Owner

Camber Pharmaceuticals, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Rufinamide is primarily used as an adjunctive therapy for seizures in epilepsy. It is often prescribed to help control partial onset seizures in adults and children. Rufinamide tablets are designed to be taken orally and are commonly used in combination with other anticonvulsant medications. What is Rufinamide used for? It is typically used to manage seizures that are not fully controlled by other treatments.

Side Effects

Rufinamide may cause dizziness, headache, and fatigue in some individuals. Other common effects include nausea, vomiting, and somnolence. It is important to monitor for any unusual side effects and consult a healthcare provider if they persist or worsen.

Precautions & Warnings

Rufinamide should be handled with care, especially by individuals with a history of heart conditions. It is important to follow the prescribed dosage and administration instructions. Rufinamide tablets should be stored at room temperature and kept out of reach of children.

Avoid Interactions

Rufinamide may interact with other medications, including those that affect liver enzymes. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Rufinamide should be used with caution when combined with alcohol or other central nervous system depressants.

Frequently Asked Questions

Rufinamide is used as an adjunctive therapy to manage seizures in epilepsy, particularly partial onset seizures.

Rufinamide tablets are designed for oral administration. Follow the dosage instructions provided by your healthcare provider.

Common side effects of Rufinamide include dizziness, headache, fatigue, nausea, vomiting, and somnolence.

Rufinamide may interact with other medications, so it is important to consult your healthcare provider before combining it with other treatments.

Rufinamide tablets should be stored at room temperature and kept out of reach of children.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.